MEDNAX Inc (NYSE:MD) gapped down before the market opened on Thursday . The stock had previously closed at $38.28, but opened at $36.64. MEDNAX shares last traded at $36.32, with a volume of 2412525 shares changing hands.
MD has been the subject of a number of recent analyst reports. Robert W. Baird lowered their price target on shares of MEDNAX from $50.00 to $48.00 and set a “neutral” rating for the company in a report on Friday, October 19th. Citigroup upgraded shares of MEDNAX from a “neutral” rating to a “buy” rating and set a $34.88 price target for the company in a report on Monday, January 14th. They noted that the move was a valuation call. UBS Group initiated coverage on shares of MEDNAX in a report on Friday, November 16th. They set a “sell” rating and a $37.00 price target for the company. Deutsche Bank initiated coverage on shares of MEDNAX in a report on Thursday, January 3rd. They set a “hold” rating and a $34.00 price target for the company. Finally, ValuEngine lowered shares of MEDNAX from a “sell” rating to a “strong sell” rating in a report on Thursday, November 1st. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $44.57.
The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.43 and a current ratio of 1.40. The firm has a market capitalization of $3.25 billion, a P/E ratio of 10.00, a price-to-earnings-growth ratio of 0.92 and a beta of 0.69.
MEDNAX (NYSE:MD) last issued its quarterly earnings data on Thursday, February 7th. The company reported $0.92 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.83 by $0.09. MEDNAX had a net margin of 7.37% and a return on equity of 10.35%. The business had revenue of $932.70 million during the quarter, compared to analyst estimates of $910.08 million. During the same period in the prior year, the business earned $0.87 EPS. The company’s revenue for the quarter was up 2.4% on a year-over-year basis. Equities analysts forecast that MEDNAX Inc will post 3.78 EPS for the current year.
In other MEDNAX news, insider John C. Pepia sold 2,500 shares of the company’s stock in a transaction on Tuesday, January 22nd. The shares were sold at an average price of $36.60, for a total value of $91,500.00. Following the completion of the transaction, the insider now directly owns 28,583 shares in the company, valued at approximately $1,046,137.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.70% of the stock is currently owned by corporate insiders.
Several large investors have recently added to or reduced their stakes in the company. Ffcm LLC grew its position in shares of MEDNAX by 137.0% in the 4th quarter. Ffcm LLC now owns 3,155 shares of the company’s stock worth $104,000 after buying an additional 1,824 shares during the period. BlackRock Inc. grew its position in MEDNAX by 1.9% during the 4th quarter. BlackRock Inc. now owns 8,511,392 shares of the company’s stock valued at $280,874,000 after purchasing an additional 159,041 shares during the last quarter. Pzena Investment Management LLC grew its position in MEDNAX by 2.8% during the 4th quarter. Pzena Investment Management LLC now owns 3,345,635 shares of the company’s stock valued at $110,406,000 after purchasing an additional 91,513 shares during the last quarter. New York State Common Retirement Fund grew its position in MEDNAX by 0.9% during the 4th quarter. New York State Common Retirement Fund now owns 721,089 shares of the company’s stock valued at $23,796,000 after purchasing an additional 6,697 shares during the last quarter. Finally, Acadian Asset Management LLC grew its position in MEDNAX by 17,761.4% during the 4th quarter. Acadian Asset Management LLC now owns 103,060 shares of the company’s stock valued at $3,403,000 after purchasing an additional 102,483 shares during the last quarter. 96.94% of the stock is currently owned by hedge funds and other institutional investors.
MEDNAX Company Profile (NYSE:MD)
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.
See Also: Fundamental Analysis and Choosing Stocks
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.